Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease

NCT02995993 | Completed Phase 1

• 1 other identifier: CT-GR-MaGal-01
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 2

Brief Summary

Six patients with Fabry disease will be recruited. Patients will receive a single dose of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion. Patients will be hospitalized during the infusion and for at least 24 hours after the end of the infusion. Treatment will be administered sequentially: if a patient shows no safety concerns on the treatment day, treatment of the next patient will commence on the following day.

Conditions

Fabry Disease

Outcome Measures

Primary Outcomes (2)

• AUC0-inf

  Area under the serum concentration curve extrapolated to infinity

  PK sampling for 24 h after moss-aGal administration

• Number of patients with drug-related adverse events

  Adverse event monitoring for 28 days after moss-aGal administration

Secondary Outcomes (3)

• Gb3 concentration in plasma

  Monitoring up to Day 28 after moss-aGal administration

• Gb3 concentration in morning urine

  Monitoring up to Day 28 after moss-aGal administration

• Lyso-Gb3 concentration in plasma

  Monitoring up to Day 28 after moss-aGal administration

Study Arms (1)

Moss-aGal

EXPERIMENTAL

Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion

Drug: Moss-aGal (recombinant human alpha-galactosidase A produced in moss)

Interventions

Moss-aGal (recombinant human alpha-galactosidase A produced in moss) DRUG

Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes

Moss-aGal

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with Fabry disease evidenced by a deficient α-galactosidase A (α-Gal A) activity or an α-Gal A gene mutation (the latter is mandatory in women);
• Treatment naïve Fabry patients or Fabry patients who paused any enzyme replacement therapy for Fabry disease due to personal reasons for 3 months before study entry;
• Female and male patients between 18 and \<=65 years;
• At least one of the clinical manifestations of Fabry disease including neuropathic pain, angiokeratoma, cornea verticillata, cardiomyopathy, hypo- or anhydrosis, abdominal pain, diarrhea, serum creatinine \>1.0 mg/dL, or proteinuria \>300 mg/24 hours;
• Lyso-Gb3 concentrations in plasma above upper limit of normal;
• Male patients with a female partner of child-bearing potential agree to use a medically acceptable method of contraception (e.g. condoms, sexual abstinence, vasectomy), not including the rhythm method for 30 days after administration of the study medication;
• Female patients of childbearing potential must apply a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly \[e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner\]). The birth control method must have been applied for at least one monthly cycle prior to the first administration of study medication and 30 days after administration of the study medication.
• Patient is willing and able (in the opinion of the investigator) to understand and comply with the procedures and evaluations of the study;
• Patient must be willing and legally able to give written informed consent.

You may not qualify if:

• Treatment with any enzyme replacement therapy for Fabry disease within 3 months before study entry;
• Fabry patients who paused any enzyme replacement therapy for Fabry disease due to intolerability;
• Patient is positive for anti-alpha-Gal A immunoglobulin G (IgG) at Screening;
• Participation in any other clinical study with a medical device or investigational medicinal product concurrently or within 3 months before study start;
• Patient is currently on dialysis, is expected to begin dialysis during the study, has received a kidney transplant, or is on the renal transplant waiting list;
• Patient is unable to comply with the protocol (e.g. clinical relevant medical condition making implementation of the protocol difficult, unstable social situation, or otherwise unlikely to complete the study) or is, in the opinion of the investigator, otherwise unsuited for the study;
• Known human immunodeficiency virus, hepatitis B surface antigen and/or hepatitis C infection;
• Known allergies or intolerabilities to enzyme replacement therapy;
• Hypersensitivity (like anaphylactic reaction) to the active substance or to any excipients of moss-aGal;
• Co-administration of moss-aGal with chloroquine, amiodarone, benoquin or gentamicin;
• Breast-feeding and pregnant women;
• Patients with liver impairment;
• Women with signs of cardiac fibrosis detectable by echocardiography;
• Other, not Fabry disease-related severe illnesses;
• Malignancies within the past 5 years;

Sponsors & Collaborators

• Greenovation Biotech GmbH: lead
• FGK Clinical Research GmbH: collaborator

Study Sites (2)

Ruhruniversität Bochum, Klinik für Kinder- und Jugendmedizin im St. Josef-Hospital im Katholischen Klinikum Bochum

Bochum, 44791, Germany

Location

Universitätsmedizin Mainz, Zentrum für Kinder- und Jugendmedizin

Mainz, 55131, Germany

Location

Related Publications (1)

• Shen JS, Busch A, Day TS, Meng XL, Yu CI, Dabrowska-Schlepp P, Fode B, Niederkruger H, Forni S, Chen S, Schiffmann R, Frischmuth T, Schaaf A. Mannose receptor-mediated delivery of moss-made alpha-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis. 2016 Mar;39(2):293-303. doi: 10.1007/s10545-015-9886-9. Epub 2015 Aug 27.

  PMID: 26310963 BACKGROUND

MeSH Terms

Conditions

Fabry Disease

Condition Hierarchy (Ancestors)

Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Cerebral Small Vessel Diseases; Cerebrovascular Disorders; Vascular Diseases; Cardiovascular Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolism, Inborn Errors; Lipidoses; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Lipid Metabolism Disorders

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2016
• First Posted: December 19, 2016
• Study Start: November 1, 2016
• Primary Completion: October 9, 2017
• Study Completion: October 9, 2017
• Last Updated: December 13, 2017

Record last verified: 2017-12

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)